BDBM171268 US9085555, 698

SMILES C[C@H](NC(=O)[C@@H]1C[C@H]2C[C@H]2N1C(=O)Cn1nc(C(N)=O)c2ccncc12)c1cccc(Cl)c1F

InChI Key InChIKey=YAALCKJNOOFODD-UHFFFAOYSA-N

Data  5 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 5 hits for monomerid = 171268   

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM171268(US9085555, 698)
Affinity DataIC50: 29nMpH: 7.5 T: 2°CAssay Description:Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compound at vario...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2016
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM171268(US9085555, 698)
Affinity DataIC50: 30nMAssay Description:Inhibition of human factor D using CVF-FB as substrate assessed as decrease in formation of factor B cleavage product Ba by ELISAMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details Article
PubMed
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM171268(US9085555, 698)
Affinity DataIC50: 70nMAssay Description:Inhibition of factor D in human serum assessed as decrease in lysis of human erythrocytes after 1 hrMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details Article
PubMed
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM171268(US9085555, 698)
Affinity DataIC50: 70nMAssay Description:Inhibition of factor D in human serum assessed as decrease in C3 deposition on human erythrocytes after 1 hrMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details Article
PubMed
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM171268(US9085555, 698)
Affinity DataIC50: 144nMAssay Description:Inhibition of factor D in human plasma assessed as decrease in alternative pathway-mediated MAC formation preincubated for 30 mins measured after 30 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details Article
PubMed